Etanercept was originally developed by Immunex, and is marketed in the US by Wyeth-Ayerst for patients with rheumatoid arthritis, where it has been shown to slow the progression of structural ...

Etanercept alone, or in combination with methotrexate, has greater efficacy than methotrexate monotherapy in patients with psoriatic arthritis, both in terms of ACR20 and minimal disease activity ...

Etanercept, originally developed by Immunex, is currently marketed in the US by Wyeth-Ayerst as Enbrel® for patients with rheumatoid arthritis (RA), where it has been shown to slow the ...

After adjusting for covariates and inverse propensity score matching, participants newly initiating treatment with etanercept (weighted hazard ratio [wHR], 0.72; 95% CI, 0.53-0.97) and ustekinumab ...

Etanercept persistence overall was 66.3% at 24 months, 49.4% at 36 months and 37.3% at 48months.

SAN FRANCISCO, CA—The efficacy and safety profiles of SB4, an etanercept biosimilar, were comparable to those of etanercept in patients with moderate to severe rheumatoid arthritis (RA) to Week ...

A multicenter pilot study of etanercept for treatment of dermatomyositis found no major safety concerns and many patients treated with the drug were successfully weaned from steroid therapy. These ...

Etanercept was associated with lower risk than mono-antibodies for general infections (relative risk, 0.66) with high heterogeneity (I ² = 79 percent).

Mean follow-up averaged 2.5 years for etanercept and 1.8 years for adalimumab. In both cases, mean follow-up was somewhat longer for patients starting the originator version.

And in those lower doses, etanercept may not be the drug everyone's hoping it is. There's still a lot more work to be done." Steroids weren't a miracle drug either.

Negotiations to set prices Medicare will pay for the original branded version of etanercept, Enbrel, should bring the government some genuine savings, and may indirectly make it more affordable ...